interleukin-12 plasmid

Interleukin-12 plasmid is a gene therapy product consisting of a plasmid DNA encoding the human interleukin-12 (IL-12) cytokine, a potent pro-inflammatory protein and immune activator. The plasmid delivers the IL-12 gene directly to the tumor site, typically by electroporation (gene electrotransfer), resulting in local expression of IL-12. This expression induces strong antitumor immunity through activation of natural killer (NK) cells, promotion of T-helper 1 (Th1) differentiation, and stimulation of cytotoxic T-lymphocyte activity. Interleukin-12 plasmids have been developed with and without antibiotic resistance genes (e.g., p21-hIL-12-ORT is an antibiotic-free construct) and are mainly under development or investigation for the treatment of solid tumors, including melanoma, cutaneous lymphoma, and basal cell carcinoma[1][2][3][4][7]. The best-known clinical formulation is tavokinogene telseplasmid (tavo), used in conjunction with in vivo electroporation (ImmunoPulse IL-12 therapy) to achieve local gene transfer and IL-12 expression.

Brand names

ImmunoPulse IL-12ImmunoPulseIL12ImmunoPulseIL-12ImmunoPulseIL 12ImmunoPulse IL12tavokinogene telseplasmid as a formulation

Other names

tavokinogene telseplasmidtavoIL-12 plasmidIL12 plasmidIL 12 plasmidinterleukin-12 DNA plasmidinterleukin12 DNA plasmidinterleukin 12 DNA plasmidIL-12 gene electrotransferIL12 gene electrotransferIL 12 gene electrotransfer